Pilot R&D and Production
https://www.sungenbiomed.com/pilot-r-d-and-production-platform/
#drug #modelling
Pilot R & D and Production Platform
Having the ability of development of small scale processes and pilot production. The expression of Fed-Batch culture reaches the international leading level.
Having drug discovery platforms of affinity chromatography, ion exchange chromatography, composite mode chromatography, nano filtration and other purification chromatography technologies. Having... morePilot R&D and Production
https://www.sungenbiomed.com/pilot-r-d-and-production-platform/
#drug #modelling
Pilot R & D and Production Platform
Having the ability of development of small scale processes and pilot production. The expression of Fed-Batch culture reaches the international leading level.
Having drug discovery platforms of affinity chromatography, ion exchange chromatography, composite mode chromatography, nano filtration and other purification chromatography technologies. Having capacity of fine purification of target antibodies and production of high purity protein stock solution.
Having a mature preparation filling platform, which produces different specifications of drug products such as pre-filled syringes, vials, and cilin bottles, and the filling accuracy exceeds the industry average level.
Molecular Discovery Platform
https://www.sungenbiomed.com/molecular-discovery-platform/
#single #b #cell #antibody #discovery
Molecular Discovery Platform
Large-capacity fully synthetic antibody library molecular discovery platform;
Hybridoma antibody molecular discovery platform;
Bispecific Antibody technology platform；
ADC technology platform with independent intellectual property
Single B cell sorting antibody molecular discovery platform;
AI-assisted antibody discovery platform wit... moreMolecular Discovery Platform
https://www.sungenbiomed.com/molecular-discovery-platform/
#single #b #cell #antibody #discovery
Molecular Discovery Platform
Large-capacity fully synthetic antibody library molecular discovery platform;
Hybridoma antibody molecular discovery platform;
Bispecific Antibody technology platform；
ADC technology platform with independent intellectual property
Single B cell sorting antibody molecular discovery platform;
AI-assisted antibody discovery platform with advanced technology.
Innovation Achievements
https://www.sungenbiomed.com/innovation-achievements/
#technological #innovations #in #biology
First in the World! Sungen Biomedical Obtains FDA's Clinical Trial Approval of IND SGC001 as An Emergency-use Antibody Drug for AMI
First in the world! Sungen Biomedical obtains FDA's clinical trial approval of IND SGC001 as an emergency-use antibody drug for AMIOn May 23rd, 2024, Eastern Standard Time, US Food and Drug Administr...
FIC! Sungen Biomedical's SGC001 Injectio... moreInnovation Achievements
https://www.sungenbiomed.com/innovation-achievements/
#technological #innovations #in #biology
First in the World! Sungen Biomedical Obtains FDA's Clinical Trial Approval of IND SGC001 as An Emergency-use Antibody Drug for AMI
First in the world! Sungen Biomedical obtains FDA's clinical trial approval of IND SGC001 as an emergency-use antibody drug for AMIOn May 23rd, 2024, Eastern Standard Time, US Food and Drug Administr...
FIC! Sungen Biomedical's SGC001 Injection is Approved for Clinical Trials, Achieving Two Approvals Both in China and the United States!
FIC! Sungen Biomedical's SGC001 Injection is Approved for Clinical Trials, Achieving Two Approvals Both in China and the United States!
On August 05, 2024, the world's first innovative drug SGC001 injection obtained the clinical trial implied approval from the Center for Drug Evaluation (CDE). The drug is developed by Beijing Sung.
Immunity
https://www.sungenbiomed.com/immunity-mast-cells-regulate-lung-inflammation-through-pge2-sst2/
#immunity
Immunity | Mast cells regulate lung inflammation through PGE2-sST2
Severe asthma and sinus disease are consequences of type 2 inflammation (T2I), mediated by interleukin (IL)-33 signaling through its membrane-bound receptor, ST2. Inhibiting IL-33 induced lung inflammation may be an effective way to control asthma. Soluble (s)ST2 reduces available IL-33 and limits T2I, but littl... moreImmunity
https://www.sungenbiomed.com/immunity-mast-cells-regulate-lung-inflammation-through-pge2-sst2/
#immunity
Immunity | Mast cells regulate lung inflammation through PGE2-sST2
Severe asthma and sinus disease are consequences of type 2 inflammation (T2I), mediated by interleukin (IL)-33 signaling through its membrane-bound receptor, ST2. Inhibiting IL-33 induced lung inflammation may be an effective way to control asthma. Soluble (s)ST2 reduces available IL-33 and limits T2I, but little is known about its regulation.
Recently, A team led by Joshua A. Boyce from Harvard Medical School published an article in the journal Immunity, titled Mast cells control lung type 2 inflammation via prostaglandin E2-driven soluble ST2. It is found that prostaglandin PGE2 can regulate respiratory mucosal mast cells, promote the production of sST2 from mast cells, and inhibit lung inflammation, which provides an important basis for the future treatment of lung inflammation and asthma.
